- Conditions
- Alzheimer's Disease
- Interventions
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
- Procedure
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 24
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease
- Interventions
- Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
- Conditions
- Alzheimer Disease
- Interventions
- Simvastatin
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Alzheimer's Disease
- Interventions
- DHA (Docosahexaenoic Acid), Placebo
- Drug
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
- Conditions
- Alzheimer's Disease
- Interventions
- Resveratrol, Placebo
- Drug
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- PF-04494700, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Irvine, California + 40 more
- Conditions
- Dementia, Alzheimer's Disease, Dementia Prevention
- Interventions
- HALT-AD
- Behavioral
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Alzheimer Disease
- Interventions
- Huperzine A
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more
- Conditions
- Alzheimer Disease
- Interventions
- Rofecoxib, Naproxen
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Irvine, California + 34 more
- Conditions
- Alzheimer's Disease
- Interventions
- T-817MA-H, T-817MA-L, Placebo
- Drug
- Lead sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
- Conditions
- Alzheimer Disease
- Interventions
- Valproate, Placebo
- Drug
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 46
- States / cities
- Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
- Conditions
- Alzheimer Disease
- Interventions
- troriluzole, Placebo oral capsule
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Memory Impairment
- Interventions
- Aerobic exercise, Stretching/balance/range of motion exercise
- Behavioral
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 65 Years to 89 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 14
- States / cities
- Irvine, California • Palo Alto, California • New Haven, Connecticut + 10 more
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Mail and Live Phone, Interactive Voice Response (IVR), Home-based Computer Kiosk, Traditional Evaluation Instruments
- Behavioral
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 23 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
- Conditions
- Down Syndrome
- Interventions
- ACI-24 low dose, ACI-24 high dose, Placebo
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • La Jolla, California • Baltimore, Maryland + 1 more
- Conditions
- Alzheimer's Disease, Disruptive Behavior
- Interventions
- Prazosin, Placebo oral capsule
- Drug
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Sun City, Arizona • Los Angeles, California • San Diego, California + 10 more
- Conditions
- Alzheimer's Disease
- Interventions
- Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Irvine, California • La Jolla, California + 10 more
- Conditions
- Alzheimer Disease
- Interventions
- Donepezil, Vitamin E
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
- Conditions
- Alzheimer's Disease
- Interventions
- CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery
- Drug · Procedure
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
- Conditions
- Alzheimer's Disease
- Interventions
- Folate, Vitamin B6, Vitamin B12
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 29 more
- Conditions
- Alzheimer Disease
- Interventions
- PQ912, Placebo
- Drug · Other
- Lead sponsor
- Vivoryon Therapeutics N.V.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
- Conditions
- Alzheimer's Disease
- Interventions
- Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more